# Kura Oncology

Type: Company (KURA)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/kura-oncology
Canonical HTML page: https://getfinancebrief.com/entity/kura-oncology

## Timeline

- **2026-Q4 (estimated)**: PROF Break-even — Target window for Profound Medical to reach cash-flow neutrality.
- **2026-Q2 (estimated)**: Kura NDA Submission — Anticipated filing for ziftomenib with the FDA.
- **2026-03-05**: Q4 Earnings Release — Both companies report pivotal year-end results.
- **2025-01-01**: CPT Code Activation — Category 1 CPT codes for TULSA-PRO go live in the U.S.

## Recent coverage (1 stories)

### Kura and Profound Signal Commercial Inflection Points in Q4 Results
2026-03-06 05:18:01 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Kura Oncology and Profound Medical reported Q4 2025 results, highlighting a pivotal shift toward commercial execution. Kura is nearing an NDA submission for its lead leukemia candidate, while Profound saw record revenue growth following the first full year of Category 1 CPT code implementation.
Full story: https://getfinancebrief.com/story/kura-oncology-profound-medical-q4-earnings-analysis-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.